Published online Sep 15, 2023. doi: 10.4251/wjgo.v15.i9.1531
Peer-review started: April 7, 2023
First decision: July 19, 2023
Revised: July 31, 2023
Accepted: August 18, 2023
Article in press: August 18, 2023
Published online: September 15, 2023
Previous studies have illustrated that integrin binding sialoprotein (IBSP) exhibits a promotive role in the progression of cancers. However, the regulatory functions of IBSP in gastric cancer (GC) progression remain unclear.
To find effective bio-targets for GC prognosis and treatment.
To probe the regulatory effects and underlying molecular mechanism of IBSP in GC progression.
Real-time quantitative polymerase chain reaction and Western blot were used to detect the mRNA and protein expression of IBSP, respectively. The prognosis of GC patients with high or low IBSP expression was evaluated. The regulatory effects of IBSP in GC progression was assessed via in vitro and in vivo experiments. The molecular mechanism of the IBSP/cleavage and polyadenylation factor 6 (CPSF6) axis was validated.
IBSP exhibited higher expression in GC, and IBSP knockdown suppressed cell proliferation, migration, and invasion but facilitated pyroptosis. Moreover, the results revealed that CPSF6 binds to the 3’-untranslated region of IBSP and positively regulates IBSP expression in GC.
Other regulatory functions and related mechanisms of ISBP in GC may be investigated in the future, and its application in GC treatment will be explored.
IBSP expression is upregulated in GC tissues and cells, which results in a poor prognosis in GC. CPSF6 positively regulates IBSP to affect pyroptosis and aggravate tumor growth in GC.